Company profile
Ticker
ORIC
Exchange
Website
CEO
Dr. Jacob M. Chacko M.B.A., M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Madison Square Garden Entertainment Corp., MSG ENTERTAINMENT SPINCO, INC.
SEC CIK
Corporate docs
IRS number
471787157
ORIC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2024 FY
Annual report
18 Feb 25
8-K
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
18 Feb 25
8-K
Regulation FD Disclosure
13 Jan 25
10-Q
2024 Q3
Quarterly report
12 Nov 24
8-K
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
12 Nov 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
12 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
6 May 24
Transcripts
Financial summary
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 59.90 mm | 59.90 mm | 59.90 mm | 59.90 mm | 59.90 mm | 59.90 mm |
Cash burn (monthly) | (no burn) | (no burn) | 13.19 mm | 11.91 mm | 9.35 mm | 9.39 mm |
Cash used (since last report) | n/a | n/a | 21.91 mm | 19.78 mm | 15.54 mm | 15.60 mm |
Cash remaining | n/a | n/a | 37.98 mm | 40.11 mm | 44.36 mm | 44.30 mm |
Runway (months of cash) | n/a | n/a | 2.9 | 3.4 | 4.7 | 4.7 |
Institutional ownership, Q3 2024
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 25 |
Closed positions | 15 |
Increased positions | 39 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 701.72 bn |
Total shares | 91.34 mm |
Total puts | 700.00 |
Total calls | 7.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 5.38 mm | $31.08 mm |
Nextech Invest | 5.29 mm | $54.18 bn |
Nextech Crossover I GP S.a r.l. | 5.29 mm | $49.79 mm |
BlackRock | 5.10 mm | $52.29 bn |
Venrock Healthcare Capital Partners III | 4.43 mm | $46.54 mm |
VR Adviser | 4.39 mm | $45.04 bn |
FMR | 4.38 mm | $44.88 bn |
Frazier Life Sciences Management | 4.14 mm | $42.46 bn |
Viking Global Investors | 4.00 mm | $41.00 bn |
Alkeon Capital Management | 3.90 mm | $40.02 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 25 | Multani Pratik S | RSU Common Stock | Grant | Acquire A | No | No | 0 | 34,000 | 0.00 | 34,000 |
2 Jan 25 | Multani Pratik S | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 202,500 | 1.67 mm | 202,500 |
2 Jan 25 | Chacko Jacob | RSU Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
2 Jan 25 | Chacko Jacob | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 600,000 | 4.96 mm | 600,000 |
2 Jan 25 | Piscitelli Dominic | RSU Common Stock | Grant | Acquire A | No | No | 0 | 34,000 | 0.00 | 34,000 |
2 Jan 25 | Piscitelli Dominic | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 202,500 | 1.67 mm | 202,500 |
2 Jan 25 | Heyman Richard A. | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 35,000 | 289.10 k | 35,000 |
2 Jan 25 | Hoerter Steven L. | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 35,000 | 289.10 k | 35,000 |
News
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
1w ago
Guggenheim Maintains Buy on ORIC Pharmaceuticalsto Buy
1w ago
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $21
1w ago
Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticalsto Overweight
1mo ago
H&E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday
1mo ago
Press releases
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
7h ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1w ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
3w ago
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
1mo ago
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
1mo ago